Acute Coronary Syndromes Fresh look at ACS in Europe, what is the real picture

The face of ACS is changing. The ageing population and pressure of growing risk factors have made a significant impact on the management strategies in ACS. This report unveils the true picture through in-depth analysis of data on over 21,000 ACS patient records in the 5 major European pharmaceutical markets (5EU; France, Germany, Italy, Spain and the UK).

Costs are no longer the restraining or dominant driver of a specific pharmacological strategy. Datamonitor's findings show that the routine use of troponins as cardiac markers has aided this development, with almost 90% of all ACS patients receiving tests for either troponin I or troponin T across the 5EU.

A new definition for myocardial infarction has shifted a significant number of patients from unclear diagnosis of unstable angina to myocardial infarction moving from an essentially conservative and observational approach to an increase in more aggressive treatment strategies.

Advances in novel imaging techniques provide opportunities to diagnose and treat the most complex ACS cases, however, inter-hospital logistics, necessary specialist training and cost constraints continue to prevent hospitals and clinicians from regular use of those diagnostic methods.

Read more...

• Urinary Incontinence (15/05/2008)
• Autoimmune Overview (15/05/2008)
• Benchmarking key countries (15/05/2008)
• Reaching Patients Through Digital Media (15/05/2008)
• CNS Market Outlook (15/05/2008)
• Growth Opportunities in Generics (15/05/2008)
• Cardiovascular Market Outlook (15/05/2008)
• Innovations in Cancer (15/05/2008)
• Dermatology Market Outlook (14/05/2008)

---